Neurodiversity Found Far More Often in Young People with Type 2 Diabetes

A sweeping analysis of health records covering more than six million people has uncovered a striking pattern: young people diagnosed with type 2 diabetes are far more likely than their peers to also be neurodivergent. The study, drawn from a large United States collaborative network of anonymised patient records and set to be presented at the Annual Meeting of the European Association for the Study of Diabetes in Milan, found that attention-deficit/hyperactivity disorder appeared roughly twice as often, and autism more than three times as often, among individuals diagnosed with type 2 diabetes before the age of twenty compared with similarly aged people who did not have the condition. The findings arrive at a moment when early-onset type 2 diabetes, defined as diagnosis before the age of forty, is rising steadily and is already known to carry a heavier burden of complications than the form that typically appears later in life. Together, the results point to a population whose clinical needs may be more complex, and less well served, than current services recognise.

The scale of the analysis lends the observation considerable weight. Researchers examined the prevalence of four neurodivergent conditions, namely ADHD, autism, dyslexia and dyspraxia, among approximately 4.2 million individuals newly diagnosed with type 2 diabetes in the TriNetX US collaborative network between March 2006 and March 2026. To account for demographic differences that might otherwise distort the comparison, each ten-year age band of people with diabetes was matched by age, year of birth, sex, ethnicity and race to individuals without the condition, drawn from a pool of 17.1 million. In total, 3.4 million matched pairs aged younger than eighty years entered the final analysis. This matching strategy is important because neurodivergent conditions are not distributed evenly across the population, and differences in sex, ethnicity or birth cohort could easily masquerade as a diabetes link if left unadjusted.

The headline numbers are most dramatic at the youngest ages. Among people diagnosed with type 2 diabetes before their twentieth birthday, ADHD reached a prevalence of 14.4 percent, compared with 6.9 percent among matched individuals of similar age without diabetes, a difference of just over twofold. Autism showed an even steeper gap, at 5.72 percent versus 1.79 percent, meaning the condition was more than three times as prevalent in the young diabetes group. Dyslexia and dyspraxia were also more common among younger people overall, and across all ages people with type 2 diabetes were roughly twice as likely to have dyslexia as those without, although this difference did not appear to follow any obvious pattern with age at diagnosis. Taken together, the data suggest that as many as one in seven young people with early-onset type 2 diabetes may also be living with ADHD, and roughly one in twenty with autism.

Age emerged as a critical variable in the analysis. Across both groups, the prevalence of neurodiversity was highest at younger ages and declined rapidly with increasing age, becoming extremely low beyond the age of forty. The gap between those with and without diabetes narrowed as age at diagnosis rose. ADHD, for example, was around 1.4 times more prevalent among people diagnosed with type 2 diabetes at seventy to seventy-nine years, at 0.25 percent versus 0.18 percent, compared with the more than twofold difference seen in the under-twenties. Autism followed the same trajectory, being 1.24 times higher in the oldest diagnostic group, although prevalence was so low in that age band, less than 0.01 percent with or without diabetes, that the comparison is difficult to interpret. The concentration of the association in youth is precisely what makes the findings clinically consequential, since early-onset diabetes is the fastest-growing and most vulnerable segment of the type 2 diabetes population.

The clinical stakes are considerable. Early-onset type 2 diabetes is associated with poorer health outcomes than later-onset disease, partly because a diagnosis at a younger age means a longer lifetime exposure to elevated blood glucose and its vascular consequences, raising the risk of serious complications and early death. Managing the condition demands sustained engagement with healthcare services, careful self-monitoring, medication adherence and lifestyle modification, all of which can be complicated by stigma and the competing demands of early adulthood, such as education, employment and establishing independence. For neurodivergent individuals, these demands can be compounded further. Busy clinics, unfamiliar environments, sensory pressures and communication barriers may make routine diabetes care genuinely difficult to navigate, potentially widening existing inequalities in outcomes.

Lead author Dr Jonathan Goldney, of the University of Leicester Diabetes Research Centre and the NIHR Biomedical Research Centre in Leicester, argued that health services are not currently equipped for this overlap. Health systems, he said, are failing to fully meet the needs of people living with both early-onset type 2 diabetes and neurodiversity, both of which are linked to poorer health outcomes. He noted that neurodivergent people and those with early-onset type 2 diabetes are likely to face unique challenges when navigating busy healthcare environments, communicating with healthcare professionals, and managing their diabetes. In his view, providing healthcare for type 2 diabetes in a way that suits neurodivergent individuals is critical to making care more accessible for everyone, particularly as diagnoses are increasingly being made earlier in life. The authors emphasise that the point is not that most neurodivergent people will develop diabetes, but that services for early-onset disease should be planned with neurodiversity in mind.

Why might neurodivergent conditions and early-onset type 2 diabetes travel together? The authors speculate that several mechanisms could contribute. Lower levels of physical activity, difficulties with sleep, the metabolic effects of certain medications, higher rates of mental health conditions and barriers to accessing healthcare could each plausibly raise cardiometabolic risk over time. Factors operating earlier in life may also matter. Maternal diabetes during pregnancy has previously been associated with altered neurodevelopmental outcomes in children as well as with later cardiometabolic risk, suggesting that shared developmental or genetic pathways could underlie part of the association. Shared genetic architecture between neurodevelopmental conditions and metabolic traits is an active area of research, and the present study was not designed to distinguish between behavioural, environmental, iatrogenic and biological explanations. Disentangling these threads is precisely what the authors say future work should address.

The observational design imposes important caveats. A study of this kind can identify associations but cannot establish cause and effect, and the influence of factors that were not measured cannot be ruled out. The analysis relied on anonymised hospital records, which may be prone to coding errors and were not collected specifically for research purposes. There is also a detection issue: people with neurodivergent conditions tend to have more frequent contact with healthcare professionals, which could increase the opportunities for a type 2 diabetes diagnosis to be made and recorded, inflating the apparent association. Furthermore, because the study only included people who had attended hospital, the sample may not be fully representative of the wider population and could exclude healthier individuals, a limitation that may have affected the prevalence estimates particularly among younger people without diabetes, where the comparison figures were very low.

Despite these limitations, the sheer size of the matched cohort makes the central signal difficult to dismiss, and the authors are clear about what should happen next. Future studies, they say, should explore the factors underlying the association between neurodivergent conditions and type 2 diabetes, and should test whether diabetes care that explicitly takes neurodiversity into account can improve health outcomes. Practical implications could include longer or more flexible appointments, adapted communication styles, sensory-considered clinic environments and closer collaboration between diabetes teams and neurodevelopmental services. The authors declare no conflicts of interest. As early-onset type 2 diabetes continues to climb among adolescents and young adults, the study suggests that recognising and accommodating neurodiversity will be an essential part of building diabetes services that work for the patients who need them most.

Subject of Research: The association between neurodivergent conditions and early-onset type 2 diabetes in a large matched cohort study

Article Title: High prevalence of neurodiversity among young people diagnosed with type 2 diabetes, suggests study of over 6 million people

Article References: High prevalence of neurodiversity among young people diagnosed with type 2 diabetes, suggests study of over 6 million people. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: type 2 diabetes, neurodiversity, ADHD, autism, early-onset diabetes, EASD, TriNetX, dyslexia, dyspraxia, health services, observational study, cardiometabolic risk